PSUF
MACK

People's United Financial’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

People's United Financial’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13
Closed – – 1108
2017
Q1 		$0 Hold
13
– – ﹤0.01% 1091
2016
Q4 		$0 Buy
+13
New +$554 ﹤0.01% 1052

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

People's United Financial's MACK Position: Q2 2017 in Review

People's United Financial sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2017, closing a stake of 13 shares.

People's United Financial first reported a position in MACK in Q4 2016 and held it in 2 quarters. The position peaked at $0 in Q1 2017. 119 funds tracked by Wall St. Rank hold MACK as of Q2 2017.

  • People's United Financial reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • People's United Financial sold 13 Merrimack Pharmaceuticals, Inc. shares in Q2 2017.
  • People's United Financial first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
  • People's United Financial's Merrimack Pharmaceuticals, Inc. position peaked at $0 in Q1 2017.
  • 119 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2017.

Based on People's United Financial's 13F filing for Q2 2017, filed 14 Aug 2017.